ReviewEye and vision (London, England)2018
Cellular therapy of the corneal stroma: a new type of corneal surgery for keratoconus and corneal dystrophies.
Review in Eye and vision (London, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 44 citations in OpenAlex.
- Induced Pluripotent Stem Cells in Corneal Regeneration: Biological Progress, Translational Barriers and Clinical Outlook.Biomedicines · 2026Review
- Bioartificial human corneas generated by tissue engineering. A historical and technical review.Histology and histopathology · 2026Review
- Subconjunctival Injection of Mesenchymal Stem Cells for Corneal Wound Healing After Chemical Injury: Impact on Epithelial Coverage, Limbal Ischemia, and Ocular Surface Inflammatory.Frontiers in medicine · 2026Article
- Current Landscape and Future Prospects of Corneal Regenerative Medicine.Ophthalmology and therapy · 2026Review
- Clinical Applications of Corneal Cells Derived from Induced Pluripotent Stem Cells.Biomolecules · 2025Review
- Mini review: human clinical studies of stem cell therapy in keratoconus.BMC ophthalmology · 2024Review
- Advanced bioengineering strategies broaden the therapeutic landscape for corneal failure.Frontiers in bioengineering and biotechnology · 2024Review
- Chemical, Physical, and Biological Corneal Decellularization Methods: A Review of Literature.Journal of ophthalmology · 2024Review
- Corneal stromal regeneration-keratoconus cell therapy: a review.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2023Review
- Cell-based Therapies for Corneal and Retinal Disorders.Stem cell reviews and reports · 2023Review
- Management of keratoconus: an updated review.Frontiers in medicine · 2023Review
- Bioprinted Membranes for Corneal Tissue Engineering: A Review.Pharmaceutics · 2022Review
- Application Prospect and Preliminary Exploration of GelMA in Corneal Stroma Regeneration.Polymers · 2022Review
- Review
- Regenerative therapy for the Cornea.Progress in retinal and eye research · 2022Review
- Advances in Regulatory Strategies of Differentiating Stem Cells towards Keratocytes.Stem cells international · 2022Review
- Primary cilia in retinal pigment epithelium development and diseases.Journal of cellular and molecular medicine · 2021Review
- Terminal Schwann Cell Aging: Implications for Age-Associated Neuromuscular Dysfunction.Aging and disease · 2021Review
- A decellularized human corneal scaffold for anterior corneal surface reconstruction.Scientific reports · 2021Article
- Cell-Free Biological Approach for Corneal Stromal Wound Healing.Frontiers in pharmacology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cellular therapy of the corneal stroma, with either ocular or extraocular stem cells, has been gaining a lot of interest over the last decade. Multiple publications from different research groups are showing its potential benefits in relation to its capacity to improve or alleviate corneal scars, improve corneal transparency in metabolic diseases by enhancing the catabolism of the accumulated molecules, generate new organized collagen within the host stroma, and its immunosuppressive and immunomodulatory properties. Autologous extraocular stem cells do not require a healthy contralateral eye and they do not involve any ophthalmic procedures for their isolation. Mesenchymal stem cells have been the most widely assayed and have the best potential to differentiate into functional adult keratocytes in vivo and in vitro. While embryonic stem cells have been partially abandoned due to ethical implications, the discovery of the induced pluripotent stem cells (iPSC) has opened a new and very promising field for future research as they are pluripotent cells with the capacity to theoretically differentiate into any cell type, with the special advantage that they are obtained from adult differentiated cells. Cellular delivery into the corneal stroma has been experimentally assayed in vivo in multiple ways: systemic versus local injections with or without a carrier. Encouraging preliminary human clinical data is already available although still very limited, and further research is necessary in order to consolidate the clinical applications of this novel therapeutic line.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.